ing to start a Phase 1/2 open label trial to study VERU-111, a novel. taxane-like oral therapy for metastatic castration resistant prostate cancer (MCRPC) that targets both alpha and beta tubulin. An Investigational New Drug (IND) application for VERU-111 is expected to be filed in O218 and the clini